Mineralys Therapeutics MLYS
NASDAQ MLYS
$23.72 -1.41 (-5.61%)
At close: Oct 1, 2026 · 4:00 PM EDT

Mineralys Therapeutics (MLYS) Liabilities and Shareholders Equity (2022 - 2026)

Updated

Mineralys Therapeutics (MLYS) posted Liabilities and Shareholders Equity of $667.85 million for Q2 2026, up 98.9% from $335.72 million a year earlier and up 2.3% from the prior quarter.

Analysis

Mineralys Therapeutics (MLYS) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends

At the end of FY2025, Mineralys Therapeutics' Liabilities and Shareholders Equity came in at $661.81 million, up 221.4% from FY2024.

  • Annual Liabilities and Shareholders Equity shows a three-year compound annual growth rate of 79.5% (FY2022 to FY2025).
  • In prior years, Mineralys Therapeutics' Liabilities and Shareholders Equity was $205.9 million in FY2024 (-18.2%), $251.64 million in FY2023 (+119.9%) and $114.44 million in FY2022.
  • The Q2 2026 figure stands as the highest quarterly Liabilities and Shareholders Equity in data going back to Q4 2022.
  • On a year-over-year basis, Liabilities and Shareholders Equity has increased in each of the last six quarters, with growth averaging 64.3% over the last eight quarters.
  • The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was Q4 2025, with growth of 221.4%; the weakest was Q4 2024, with a decline of 18.2%.
  • According to Business Quant data, Liabilities and Shareholders Equity for the three prior quarters was $652.86 million (Q1 2026), $661.81 million (Q4 2025) and $599.95 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Mineralys Therapeutics 2.22 Bn 2.22 Bn - 667.85 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 667.85 Mn
Mar 31, 2026 652.86 Mn
Dec 31, 2025 661.81 Mn
Sep 30, 2025 599.95 Mn
Jun 30, 2025 335.72 Mn
Mar 31, 2025 354.94 Mn
Dec 31, 2024 205.90 Mn
Sep 30, 2024 268.25 Mn
Jun 30, 2024 318.49 Mn
Mar 31, 2024 347.25 Mn
Dec 31, 2023 251.64 Mn
Sep 30, 2023 277.56 Mn
Jun 30, 2023 291.22 Mn
Mar 31, 2023 306.44 Mn
Dec 31, 2022 114.44 Mn
API Access

Mineralys Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=MLYS&period=max&api_key=YOUR_API_KEY